Therapeutic compositions for treating pain via multiple targets

US12152243B2 · kind B2 · utility

Assignee

• QuellTx, Inc. · US

Inventors

• Graham T. Dempsey · Cambridge, US
• Owen McManus · North Plainfield, US
• Hongkang Zhang · Wellesley, US
• David J. Gerber · Hartford, US
• Pin Liu · Zhengzhou, CN
• Dawei Zhang · Saratoga, US
• Duncan Brown · Berkeley, US
• Sudhir Agrawal · Shrewsbury, US
• Caitlin Lewarch · Cambridge, US

Key dates

• Filing date: Sep 17, 2021
• Grant date: Nov 26, 2024
• Expiry date: Sep 17, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides non-opioid pain therapeutic compositions that include an antisense oligonucleotide (ASO) complementary to an identified target on a NaV channel mRNA. The ASO hybridizes to its target RNA and forms a duplex that recruits RNase H to degrade the RNA, thereby downregulating NaV channel synthesis, which inhibits the neuron's ability to contribute to the perception of pain. The ASO targets one of the specific identified targets, and may be provided as a gapmer that includes a central DNA segment flanked by modified RNA wings. When the composition is delivered to dorsal root ganglion (DRG) neurons in vitro, the DRG neurons exhibit a dose-dependent knockdown of NaV1.7, NaV1.8, or NaV1.9.